{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:54:32Z","timestamp":1783814072051,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Diagnostic Pathology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.semdp.2023.04.005","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T11:33:37Z","timestamp":1681299217000},"page":"195-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Genomics of myelodysplastic\/myeloproliferative neoplasm"],"prefix":"10.1053","volume":"40","author":[{"given":"Pranav Pramod","family":"Patwardhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aarabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0277-0132","authenticated-orcid":false,"given":"Nidhi","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semdp.2023.04.005_bib0001","first-page":"228","author":"Kanagal-Shamanna","year":"2018","journal-title":"Cancer Genet"},{"issue":"20","key":"10.1053\/j.semdp.2023.04.005_bib0002","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.semdp.2023.04.005_bib0003","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00277-009-0745-3","article-title":"Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS\/MPN category","volume":"88","author":"Bacher","year":"2009","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1053\/j.semdp.2023.04.005_bib0004","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.semdp.2023.04.005_bib0005","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.005_bib0006","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41375-019-0574-x","article-title":"Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients","volume":"34","author":"Mangaonkar","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.semdp.2023.04.005_bib0007","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/ajh.25592","article-title":"The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia","volume":"94","author":"Zheng","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1053\/j.semdp.2023.04.005_bib0008","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/ijlh.13659","article-title":"The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic\/myeloproliferative neoplasm","volume":"43","author":"Ibrar","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"S1","key":"10.1053\/j.semdp.2023.04.005_bib0009","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.5045\/br.2021.2020321","article-title":"Diagnosis and treatment of chronic myelomonocytic leukemia","volume":"56","author":"Kwon","year":"2021","journal-title":"Blood Res"},{"issue":"12","key":"10.1053\/j.semdp.2023.04.005_bib0010","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.leukres.2011.06.001","article-title":"Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry","volume":"35","author":"Neukirchen","year":"2011","journal-title":"Leuk Res"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.005_bib0011","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.leukres.2014.11.025","article-title":"The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands","volume":"39","author":"Dinmohamed","year":"2015","journal-title":"Leuk Res"},{"issue":"12","key":"10.1053\/j.semdp.2023.04.005_bib0012","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2018-08-867333","article-title":"The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis","volume":"133","author":"Cargo","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.semdp.2023.04.005_bib0013","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and Treatment of chronic myelomonocytic leukemias in adults: recommendations from the european hematology association and the european leukemiaNet","volume":"2","author":"Itzykson","year":"2018","journal-title":"Hemasphere"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.005_bib0014","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.25684","article-title":"Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management","volume":"95","author":"Patnaik","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1053\/j.semdp.2023.04.005_bib0015","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"issue":"19","key":"10.1053\/j.semdp.2023.04.005_bib0016","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.semdp.2023.04.005_bib0017","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","article-title":"Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients","volume":"34","author":"Coltro","year":"2020","journal-title":"Leukemia"},{"key":"10.1053\/j.semdp.2023.04.005_bib0018","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1038\/bcj.2015.113","article-title":"Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.005_bib0019","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.24581","article-title":"DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.005_bib0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-017-0045-4","article-title":"EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental","volume":"8","author":"Patnaik","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1053\/j.semdp.2023.04.005_bib0021","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.semdp.2023.04.005_bib0022","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/leu.2017.164","article-title":"Genomic determinants of chronic myelomonocytic leukemia","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"10.1053\/j.semdp.2023.04.005_bib0023","first-page":"5716","article-title":"SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1053\/j.semdp.2023.04.005_bib0024","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1038\/s41375-020-0752-x","article-title":"Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS\/MPN overlap neoplasms","volume":"34","author":"DiFilippo","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.005_bib0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ajh.24939","article-title":"Therapy related-chronic myelomonocytic leukemia (CMML): molecular, cytogenetic, and clinical distinctions from de novo CMML","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.005_bib0026","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00428-022-03465-7","article-title":"Advances in myelodysplastic\/myeloproliferative neoplasms","volume":"482","author":"Prakash","year":"2023","journal-title":"Virchows Arch"},{"issue":"12","key":"10.1053\/j.semdp.2023.04.005_bib0027","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1182\/blood-2005-05-2164","article-title":"Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations","volume":"106","author":"Dohner","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.005_bib0028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/ejh.12549","article-title":"Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation","volume":"96","author":"Peng","year":"2016","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1053\/j.semdp.2023.04.005_bib0029","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/modpathol.2012.218","article-title":"Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia","volume":"26","author":"Courville","year":"2013","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1053\/j.semdp.2023.04.005_bib0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.semdp.2023.04.005_bib0031","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.23846","article-title":"Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study","volume":"89","author":"Wassie","year":"2014","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1053\/j.semdp.2023.04.005_bib0032","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1158\/1078-0432.CCR-15-2781","article-title":"A multi-institution phase i trial of ruxolitinib in patients with Chronic Myelomonocytic Leukemia (CMML)","volume":"22","author":"Padron","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1053\/j.semdp.2023.04.005_bib0033","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.2021011323","article-title":"Relationship between clone metrics and clinical outcome in clonal cytopenia","volume":"138","author":"Galli","year":"2021","journal-title":"Blood"},{"issue":"5-6","key":"10.1053\/j.semdp.2023.04.005_bib0034","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/10428199209049789","article-title":"Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia","volume":"7","author":"Galton","year":"1992","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.005_bib0035","first-page":"14","article-title":"Atypical chronic myeloid leukaemia - a rare subtype of myelodysplastic\/myeloproliferative neoplasm","volume":"22","author":"Drozd-Sokolowska","year":"2018","journal-title":"Contemp Oncol (Pozn)"},{"issue":"6","key":"10.1053\/j.semdp.2023.04.005_bib0036","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.24722","article-title":"Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1053\/j.semdp.2023.04.005_bib0037","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.leukres.2008.04.024","article-title":"Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm","volume":"32","author":"Fend","year":"2008","journal-title":"Leuk Res"},{"issue":"3","key":"10.1053\/j.semdp.2023.04.005_bib0038","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.semdp.2023.04.005_bib0039","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.183160","article-title":"The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic\/myeloproliferative neoplasms","volume":"103","author":"Meggendorfer","year":"2018","journal-title":"Haematologica"},{"issue":"10","key":"10.1053\/j.semdp.2023.04.005_bib0040","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.005_bib0041","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-022-00622-8","article-title":"Myelodysplastic\/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients","volume":"12","author":"Mangaonkar","year":"2022","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1053\/j.semdp.2023.04.005_bib0042","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.3324\/haematol.2014.119032","article-title":"Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations","volume":"100","author":"Jeromin","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.semdp.2023.04.005_bib0043","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ajh.24332","article-title":"Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1053\/j.semdp.2023.04.005_bib0044","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.semdp.2023.04.005_bib0045","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2018-05-848473","article-title":"Mutational landscape of myelodysplastic\/myeloproliferative neoplasm-unclassifiable","volume":"132","author":"Bose","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.semdp.2023.04.005_bib0046","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1002\/cncr.26537","article-title":"Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic\/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53","volume":"118","author":"Kanagal-Shamanna","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.005_bib0047","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2141.1999.01537.x","article-title":"Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder\/myelodysplastic syndrome with an aggressive clinical course","volume":"106","author":"McClure","year":"1999","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1053\/j.semdp.2023.04.005_bib0048","doi-asserted-by":"crossref","first-page":"14251","DOI":"10.18632\/oncotarget.7350","article-title":"Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS","volume":"7","author":"Kanagal-Shamanna","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1053\/j.semdp.2023.04.005_bib0049","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41379-021-00961-0","article-title":"Myelodysplastic\/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group","volume":"35","author":"Kanagal-Shamanna","year":"2022","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1053\/j.semdp.2023.04.005_bib0050","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.227686","article-title":"Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a \"grey zone\" combination of myelodysplastic and myeloproliferative features?","volume":"105","author":"Sangiorgio","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.005_bib0051","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/hematology.2020000130","article-title":"Genomics of myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes","volume":"2020","author":"Patnaik","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Seminars in Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257023000345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257023000345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:23:32Z","timestamp":1760037812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740257023000345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0740257023000345"],"URL":"https:\/\/doi.org\/10.1053\/j.semdp.2023.04.005","relation":{},"ISSN":["0740-2570"],"issn-type":[{"value":"0740-2570","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomics of myelodysplastic\/myeloproliferative neoplasm","name":"articletitle","label":"Article Title"},{"value":"Seminars in Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semdp.2023.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}